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observed event rates for depression and ischaemic heart 
disease seemed to be higher than expected in a general 
population.10 Reframing these observations, however, 
conﬁ rms what clinicians have known for decades: 
nicotine addiction represents a profound disturbance 
in brain biology, manifesting as a compulsive disorder 
with a wide array of predictable consequences. In 
other words, ischaemic events, depression, and other 
neuropsychiatric eﬀ ects might be a function of tobacco 
dependence and recovery, rather than an eﬀ ect of the 
drug choices made during treatment.
Treating tobacco dependence involves a series of 
personal and professional calculations, sometimes 
messy and coloured by intense emotions. Against this 
backdrop, the implications of Kotz and colleagues’ study 
go beyond its obvious points regarding varenicline side-
eﬀ ects. To understand the true relevance of this work 
requires placing it within historical context, and asking 
some diﬃ  cult questions about our own risk-aversive 
nature. For the past decade, clinicians have been faced 
with opposing signals from the ﬁ eld. Are adverse events 
a function of the treatment or the disease? Exactly 
how safe does a safe medication need to be when 
weighed against the burden of illness caused by tobacco 
dependence? Should reliance on anecdotal case reports 
be allowed when making treatment decisions? How big 
do observational studies need to be before the guidance 
they provide can be trusted? Would the answers to these 
questions be diﬀ erent if the questions weren’t about 
smoking? By providing precise risk estimates associated 
with the treatment options, Kotz and colleagues’ study 
should allow us to move on comfortably, and begin to 
examine the nature of our internal calculus of risk with 
respect to what remains as the single greatest cause of 
premature death and disability around the world.
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 Elucidating COPD pathogenesis by large-scale genetic analyses
Chronic obstructive pulmonary disease (COPD) is a 
heterogeneous syndrome deﬁ ned by the presence of 
chronic airﬂ ow limitation and associated with other 
clinical and pathological hallmarks, such as chronic 
bronchitis, emphysema, exacerbations, and comorbidities. 
COPD is a complex disease, suggesting that both genetic 
susceptibility and environmental exposures (eg, cigarette 
smoking and smoke from biomass fuels) contribute to its 
pathogenesis (ﬁ gure). In The Lancet Respiratory Medicine, 
Louise Wain and colleagues1 report intriguing novel 
insights into the genetics of smoking behaviour and the 
airﬂ ow obstruction component of COPD.
The genetic study done by the UK Biobank Lung Exome 
Variant Evaluation (UK BiLEVE) collaborators has many 
assets.1 First, big is beautiful in genetics. More than 
500 000 individuals have been included in UK Biobank, 
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and more than 50 000 individuals of European ancestry 
were examined in the current study on lung function 
genetics. Second, the investigators applied a smart 
sampling strategy, selecting individuals from the middle 
and extremes of the distribution of lung function (FEV1) 
among both never smokers and heavy smokers. Thanks 
to this nested case-control study design, they enriched the 
large sample for non-smoking participants with airﬂ ow 
limitation, in whom genetic risk factors are suspected to 
play a more important part. Third, they used a new custom 
Aﬀ ymetrix array to undertake genome-wide genotyping 
of 807 411 variants, encompassing common (minor allele 
frequency [MAF] >5%) single nucleotide polymorphisms 
(SNPs), low-frequency variants (MAF 1–5%), and rare 
(MAF <1%) coding variants relevant to the UK population. 
Moreover, by using the 1000 Genomes and UK10K 
reference panels, this genotyping array provided the 
unprece dented opportunity to look for association with 
28 509 962 genetic variants—imputed or genotyped—in 
each individual. Multiplying 28·5 million genetic variants 
by 50 000 participants leads to 1·425 × 10¹² variants 
analysed—an astronomical number. 
What are the main ﬁ ndings? In the genetic association 
analyses of smoking behaviour, the investigators 
conﬁ rmed the strong association with the nicotinic 
acetylcholine receptors CHRNA3 and CHRNA5 at the 
15q25 locus, and discovered ﬁ ve novel regions of 
association in or near NCAM1, TEX41/PABPC1P2, DNAH8, 
NOL4L, and LPPR5 (all p<5 × 10–⁸). For reasons of brevity, 
we will focus on the NCAM1 gene, a membrane-bound 
glycoprotein that mediates adhesion among neurons. 
Two of the novel signals suggest a functional role for 
NCAM1 in nicotine addiction, since one SNP (rs4466874) 
was located in an intron of NCAM1 on chromosome 11, 
and another SNP (rs10193706) located distantly on 
chromosome 2 modulates the level of expression of 
NCAM1 in brain tissue. Moreover, this second SNP is also 
an expression quantitative trait locus for the gene WDR61 
in the substantia nigra, which plays an important part in 
reward and addiction.
What insights did the genetic analyses of lung function 
and COPD provide? Comparing individuals with low FEV1 
with those with high FEV1, the investigators discovered 
ﬁ ve novel genetic loci of lung function: NPNT, TET2, 
HLA-DQB1/HLA-DQA2, KANSL1, and TSEN54. The lead 
SNPs at these loci were more strongly associated with 
low FEV1 in never smokers (all p<5×10–⁸) than in heavy 
smokers, and were also associated with COPD (deﬁ ned by 
spirometry as FEV1:FVC ratio <0·7 and percent predicted 
FEV1<80%). This ﬁ nding might be surprising, since a low 
FEV1 can be caused by airﬂ ow obstruction—as in asthma 
or COPD—or by decreased lung volumes (ie, a restrictive 
syndrome due to heart failure, interstitial lung disease, 
or obesity). However, these ﬁ ndings are in line with 
recent evidence of diﬀ erent trajectories of lung function 
in the pathogenesis of COPD;2 about half of the patients 
have an accelerated decline in lung function, whereas 
the other half have a normal decline, starting from an 
already impaired lung function at the age of 20–40 years 
caused by impaired lung development or growth, or 
both.2 The investigators conﬁ rmed that the HHIP gene, 
which is involved in fetal lung development and is one of 
the top hits of the ﬁ rst genome-wide association studies 
of lung function, is a COPD susceptibility gene.3 
Figure: Genetic susceptibility to chronic obstructive pulmonary disease
Genetic variants contribute to the pathogenesis ofchronic obstructive pulmonary disease through three diﬀ erent pathways: (A) genes expressed in the brain might be involved in nicotine addiction 
(smoking behaviour); (B) genes expressed in the lungs during fetal life or childhood, or both, might impair lung development and growth in early life; and (C) genes expressed in the lungs might 
accelerate the decline in lung function in adulthood. Genetic variation in oxidative stress responses, adaptive immunity—including autoimmune responses—and epigenetic regulation (eg, DNA 
methylation and histone modiﬁ cations) modulate host responses to cigarette smoke and other air pollutants.
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Several of the newly discovered genes implicate 
epigenetic regulation in the pathogenesis of COPD. 
Epigenetic mechanisms modulate the expression of 
genes by regulating the methylation of DNA or by 
modifying histones within chromatin. KANSL1 encodes 
a key subunit of the histone acetyltransferase complex 
NSL1. Findings from pharmacological and genetic 
studies4,5 have shown roles for histone deacetylases 
HDAC2 and HDAC4 in the pathogenesis of COPD.4,5 
Since the amount of acetylation of histones within the 
nucleus determines to what extent speciﬁ c regions of 
DNA are accessible to transcription factors, and thus 
gene activation, these genetic variants might modulate 
inﬂ ammatory responses in the lungs. The gene TET2 
encodes methylcytosine dioxygenase 2, which catalyses 
the conversion of 5-methylcytosine to 5-hydroxy-
methylcytosine to mediate DNA methylation. TET2, 
together with key transcription factors, regulates 
the diﬀ erentiation of Th1 and Th17 CD4+ T cells 
and promotes the expression of interferon-γ and 
interleukin-17 in these lymphocytes, which suggests 
that TET2 has a role in autoimmune diseases.6 Moreover, 
the association of low FEV1 with the HLA region on 
chromosome 6 (HLA-DQB1) also suggests that adaptive 
immune responses such as Th17 responses might 
contribute to the development of COPD.1,7 Although the 
HLA region has been associated with allergic asthma,8 
the genetic association persisted in individuals without 
doctor-diagnosed asthma. 
What are the next steps? First, the novel genetic 
associations with lung function and COPD should be 
replicated in independent cohorts and investigated in 
people of other ethnic origins. Second, the causative 
SNPs need to be discovered through ﬁ ne mapping and 
the functional role of the putative genes need to be 
elucidated through translational research approaches. 
Third, we are looking forward to new genetic studies 
in UK Biobank that investigate other lung function 
measurements (eg, FVC and FEV1:FVC ratio) and other 
hallmarks of COPD such as chronic bronchitis and 
emphysema. Thanks to the vast number of participants, 
the optimum genotyping arrays, and the smart study 
designs in UK Biobank, the future looks bright for 
unravelling the genetic cause of COPD. 
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Towards an integrative genomics of lung function
Genetic variation is an important determinant of lung 
function and risk of chronic obstructive pulmonary 
disease (COPD). Genome-wide association studies 
(GWAS), ﬁ rst described a decade ago, have become the 
standard method t o study genetic factors inﬂ uencing 
these and other complex (non-mendelian) traits and 
diseases. GWAS can be used to identify novel biological 
pathways for human disease and ultimately inform 
diagnostics and therapeutics.1 However, they have 
several limitations. One is a lack of power. Although 
GWAS in most diseases have identiﬁ ed at least a few 
genetic loci, important insights can only be gained 
when patterns among many loci are recognised.2 To 
detect such patterns, however, large sample sizes are 
needed, and these can be diﬃ  cult to achieve. Another 
major limitation is that GWAS generally implicate 
regions of the genome rather than speciﬁ c genes or 
pathophysiological mechanisms.
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